Rhenman & Partners Asset Management Ab Uni Qure N.V. Transaction History

Rhenman & Partners Asset Management Ab

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 19, 2021	SELL	$35.35 - $50.67 $1.43 Million - $2.05 Million	-40,466 Closed	0 $0
Q2 2020 Jul 16, 2020	SELL	$45.06 - $67.74 $1.14 Million - $1.72 Million	-25,332 Reduced 38.5%	40,466 $1.82 Million
Q1 2020 Apr 16, 2020	BUY	$40.01 - $73.97 $231,977 - $428,878	5,798 Added 9.66%	65,798 $3.12 Million
Q4 2019 Jan 17, 2020	BUY	$37.13 - $74.62 $2.23 Million - $4.48 Million	60,000 New	60,000 $4.3 Million

155

40.8M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $664M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.